JP2024518712A - Ｋｄｍ４阻害剤による癌の処置 - Google Patents

Ｋｄｍ４阻害剤による癌の処置 Download PDF

Info

Publication number
JP2024518712A
JP2024518712A JP2023562492A JP2023562492A JP2024518712A JP 2024518712 A JP2024518712 A JP 2024518712A JP 2023562492 A JP2023562492 A JP 2023562492A JP 2023562492 A JP2023562492 A JP 2023562492A JP 2024518712 A JP2024518712 A JP 2024518712A
Authority
JP
Japan
Prior art keywords
cancer
fold
diagnosed
patient
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023562492A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024518712A5 (https=
Inventor
ペラーボ，フランク
スタッフォード，ジェフリー・エイ
クラーク，マイケル
チェン，ヤン・ケイ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celgene Corp
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of JP2024518712A publication Critical patent/JP2024518712A/ja
Publication of JP2024518712A5 publication Critical patent/JP2024518712A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2023562492A 2021-04-09 2022-04-08 Ｋｄｍ４阻害剤による癌の処置 Pending JP2024518712A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163173219P 2021-04-09 2021-04-09
US63/173,219 2021-04-09
US202163252542P 2021-10-05 2021-10-05
US63/252,542 2021-10-05
US202263297960P 2022-01-10 2022-01-10
US63/297,960 2022-01-10
PCT/US2022/024087 WO2022217100A1 (en) 2021-04-09 2022-04-08 Treatment of cancer with kdm4 inhibitors

Publications (2)

Publication Number Publication Date
JP2024518712A true JP2024518712A (ja) 2024-05-02
JP2024518712A5 JP2024518712A5 (https=) 2025-04-16

Family

ID=83545127

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023562492A Pending JP2024518712A (ja) 2021-04-09 2022-04-08 Ｋｄｍ４阻害剤による癌の処置

Country Status (6)

Country Link
US (1) US20250025451A1 (https=)
EP (1) EP4319748A4 (https=)
JP (1) JP2024518712A (https=)
AU (1) AU2022254741A1 (https=)
CA (1) CA3214399A1 (https=)
WO (1) WO2022217100A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3600301B1 (en) 2017-03-30 2024-07-03 Albert-Ludwigs-Universität Freiburg Kdm4 inhibitors
KR20250067936A (ko) * 2022-09-21 2025-05-15 셀진 코포레이션 3-(｛[(4r)-7-｛메틸[4-(프로판-2-일)페닐]아미노｝-3,4-디하이드로-2h-1-벤조피란-4-일]메틸｝아미노)피리딘-4-카르복실산l-라이신 염의 결정형, 히스톤 탈메틸화효소 억제제

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017523152A (ja) * 2014-06-25 2017-08-17 セルジーン クオンティセル リサーチ，インク． ヒストンデメチラーゼ阻害剤
JP2020515645A (ja) * 2017-03-30 2020-05-28 アルベルト−ルートヴィヒ−ユニバーシティー フライブルク Ｋｄｍ４阻害剤

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0307643D0 (en) * 2003-04-02 2003-05-07 Cyclacel Ltd Markers
UY35395A (es) * 2013-03-12 2014-10-31 Abbvie Inc Inhibidores de bromodominios tetracíclicos
WO2019083594A1 (en) * 2017-08-21 2019-05-02 The General Hospital Corporation COMPOSITIONS AND METHODS FOR CLASSIFYING TUMORS WITH INSTABILITY OF MICROSATELLITES
UY38349A (es) * 2018-08-30 2020-03-31 Array Biopharma Inc Compuestos de pirazolo[3,4-b]piridina como inhibidores de cinasas tam y met
WO2023023112A1 (en) * 2021-08-18 2023-02-23 Celgene Corporation Process for preparing histone demethylase inhibitors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017523152A (ja) * 2014-06-25 2017-08-17 セルジーン クオンティセル リサーチ，インク． ヒストンデメチラーゼ阻害剤
JP2020515645A (ja) * 2017-03-30 2020-05-28 アルベルト−ルートヴィヒ−ユニバーシティー フライブルク Ｋｄｍ４阻害剤

Also Published As

Publication number Publication date
EP4319748A1 (en) 2024-02-14
WO2022217100A1 (en) 2022-10-13
EP4319748A4 (en) 2025-02-26
AU2022254741A1 (en) 2023-11-16
US20250025451A1 (en) 2025-01-23
CA3214399A1 (en) 2022-10-13

Similar Documents

Publication Publication Date Title
Wong et al. In colorectal cancer cells with mutant KRAS, SLC25A22-mediated glutaminolysis reduces DNA demethylation to increase WNT signaling, stemness, and drug resistance
KR20240000534A (ko) Raf 억제제를 이용하는 암의 치료
Si et al. Prevalence of BRAF V600E mutation in Chinese melanoma patients: large scale analysis of BRAF and NRAS mutations in a 432-case cohort
JP2022017495A (ja) 癌を治療するための併用療法
Shang et al. Focal adhesion kinase and β‐catenin cooperate to induce hepatocellular carcinoma
US12539303B2 (en) RET inhibitor for use in treating cancer having a RET alteration
US10201516B2 (en) Targeting K-Ras-mediated signaling pathways and malignancy by prostratin
KR20220123064A (ko) Cdk12/13 억제제에 의한 암 치료
JP2024518712A (ja) Ｋｄｍ４阻害剤による癌の処置
WO2014113820A1 (en) Estrogen receptor inhibitors
Soucie et al. Molecular basis of mast cell disease
CN116209452A (zh) 用于治疗aml的疗法和rara激动剂、低甲基化剂和bcl-2抑制剂的用途
EP4501328A1 (en) Biomarker for treatment of solid cancer by imidazo[4,5-b]pyridine derivative
US20210079384A1 (en) Non-invasive detection of response to a targeted therapy
JPWO2019039390A1 (ja) 若年性骨髄単球性白血病治療薬
US20200010904A1 (en) Method of predicting effects of cdc7 inhibitor
Jean-Yves et al. Gastrointestinal stromal tumours (primer)
US20260116962A1 (en) Plk1 inhibitor in combination with anti-angiogenics for treating metastatic cancer
US8697681B2 (en) Method for prediction of therapeutic effect of chemotherapy employing expression level of dihydropyrimidine dehydrogenase gene as measure
HK40081065A (en) Treatment of cancer with cdk12/13 inhibitors
JPWO2011078312A1 (ja) 肝細胞癌患者に対する化学療法の治療効果予測方法
JPWO2004093858A1 (ja) Ｍｍｐ発現抑制剤
CA3036568C (en) Methods for treating ovarian cancer
WO2025172576A1 (en) Methods of treatment of cancer with gspt1 degraders
WO2025160221A1 (en) Myc amplification drives resistance to pan-ras inhibitors in pancreatic cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250408

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250408

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260227

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260303